Completed
PHASE2
INTERVENTIONAL
NCT03311724
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The purpose of this study is to determine the efficacy of tirzepatide in participants with type 2 diabetes.
Interventions
Name:
Tirzepatide
Type:
DRUG
Description:
Administered SC
Name:
Placebo
Type:
DRUG
Description:
Administered SC
Primary Outcomes
Measure:
Change From Baseline in Haemoglobin A1c (HbA1c)
TimeFrame:
Baseline, 3 Months
Description:
Least squares (LS) mean was calculated using mixed model repeated measures model (MMRM) with baseline + baseline BMI group + baseline metformin flag + treatment + time + treatment\*time as fixed factors.
Trial Information
NCT ID
NCT03311724
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE2
Sponsor
Eli Lilly and Company
Last Updated
December 15, 2025